Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson's Disease.

International journal of molecular sciences - 11 Nov 2021

Pierzchlińska Anna, Droździk Marek, Białecka Monika

Abstract excerpt

Parkinson's disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors-statins-via both cholesterol-dependent and independent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Variation
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl CoA Reductases

Share to Neuroprotective Agents

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 34830081
DOI: 10.3390/ijms222212198
PMCID: PMC8620375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson's Disease.PMID 34830081Read ↗

Genetic Polymorphisms in the HMGCR Gene and Associations with Cognitive Decline in Parkinson's Disease Patients.Semantic proximity Read ↗

Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Astrocytic HMGCR-Mediated Cholesterol Alleviated Parkinson's Disease Phenotypes by Inhibiting NF-κB Neuroinflammation.Semantic proximity Read ↗

High‐mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approachesSemantic proximity Read ↗

Impact of genetic variants of apolipoprotein E on lipid profile in patients with Parkinson's disease.Semantic proximity Read ↗

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.Semantic proximity Read ↗

The impairment of cholesterol metabolism in Huntington disease.Semantic proximity Read ↗

Evaluating lipid-lowering drug targets for Parkinson disease prevention with Mendelian randomizationSemantic proximity Read ↗

Study of cholesterol metabolism in Huntington's disease.Semantic proximity Read ↗

The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration.Semantic proximity Read ↗

The cholesterol 24-hydroxylase enzyme, CYP46A1, reduces overexpressed alpha-synuclein proteins in human cellular models of Parkinson’s disease.Semantic proximity Read ↗

Update on epidemiological aspects of progressive supranuclear palsy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.